Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment
Konrad Rejdak, Paweł Grieb
Topics & Concepts
MedicineMultiple sclerosisAmantadineDiseaseParkinsonismCoronavirus disease 2019 (COVID-19)CoronavirusOutbreakPandemicPediatricsImmunologyInternal medicineInfectious disease (medical specialty)VirologyLong-Term Effects of COVID-19COVID-19 Clinical Research StudiesCOVID-19 and Mental Health